Hutchmed (China) Limited
Biopharmaceutical firm developing targeted therapies for cancer and immune diseases.
HCM | HKEX
Overview
Corporate Details
- ISIN(s):
- KYG4672N1198 (+1 more)
- LEI:
- 2138006X34YDQ6OBYE79
- Country:
- Hong Kong
- Address:
- LEVEL 18, THE METROPOLIS TOWER, KOWLOON
- Website:
- https://www.hutch-med.com/
- Sector:
- Manufacturing
Description
Hutchmed is a commercial-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapeutics and immunotherapies. The company operates a fully integrated platform, advancing a pipeline of novel drug candidates for the treatment of cancer and immunological diseases. Its research and development strategy focuses on creating highly selective and potent therapies engineered to improve drug exposure and reduce off-target toxicities. Hutchmed has multiple internally discovered medicines approved and marketed for various oncology and immunology indications, supported by a global commercialization infrastructure.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-07-07 08:00 |
Notification of Dilution of Voting Rights
|
English | 14.4 KB | ||
| 2020-06-29 08:00 |
Blocklisting Six Monthly Return
|
English | 26.9 KB | ||
| 2020-06-26 08:00 |
Notice of Results
|
English | 13.8 KB | ||
| 2020-06-25 08:15 |
$100 Million Equity Investment by General Atlantic
|
English | 25.6 KB | ||
| 2020-06-18 09:15 |
Fruquintinib Granted US FDA Fast Track Designation
|
English | 24.9 KB | ||
| 2020-06-09 08:00 |
US$95m Guangzhou Land Compensation Agreement
|
English | 15.7 KB | ||
| 2020-06-04 08:00 |
Continuation of Phase III FRUTIGA Study
|
English | 21.0 KB | ||
| 2020-06-02 17:40 |
Second Price Monitoring Extn
|
English | 2.4 KB | ||
| 2020-06-02 17:37 |
Price Monitoring Extension
|
English | 2.4 KB | ||
| 2020-06-01 08:00 |
Chi-Med Plans to Submit US NDA for Surufatinib
|
English | 21.2 KB | ||
| 2020-05-29 14:00 |
Chi-Med to Discuss Data Presented at ASCO20
|
English | 28.9 KB | ||
| 2020-05-29 08:00 |
NDA Acceptance in China for Savolitinib
|
English | 21.3 KB | ||
| 2020-05-26 08:00 |
Chi-Med and BeiGene Enter Clinical Collaboration
|
English | 35.0 KB | ||
| 2020-05-14 08:00 |
Clinical Data to be Presented at ASCO20
|
English | 28.4 KB | ||
| 2020-05-11 17:41 |
Second Price Monitoring Extn
|
English | 2.4 KB |
Automate Your Workflow. Get a real-time feed of all Hutchmed (China) Limited filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Hutchmed (China) Limited
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Hutchmed (China) Limited via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
